Literature DB >> 22716151

Gene-environment interactions underlying the effect of cannabis in first episode psychosis.

Jose Maria Pelayo-Terán1, Paula Suárez-Pinilla, Nicholas Chadi, Benedicto Crespo-Facorro.   

Abstract

Cannabis use may be considered as an additional risk factor in a diathesis-stress model of schizophrenia where the risk of developing the illness would be higher in genetic vulnerable people. In this regard, much of the research on cannabis and psychosis is currently focusing on gene-environment interactions. The present review will focus on the interaction between genes and cannabis exposure in the development of psychotic symptoms and schizophrenia and the biological mechanisms of cannabis. Cannabis use has been shown to act together with other environmental factors such as childhood trauma or urbanicity producing synergistic dopamine sensitization effects. Studies on gene-environment interaction have mainly included genetic variants involved in the regulation of the dopaminergic system. The most promising genetic variants in this field are COMT, CNR1, BDNF, AKT1 and NRG1. Additionally, the interaction with other environmental factors and possible gene-gene interactions are considered in the etiological model.

Entities:  

Mesh:

Year:  2012        PMID: 22716151     DOI: 10.2174/138161212802884609

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  13 in total

1.  New findings in the genetics of schizophrenia.

Authors:  Ladislav Hosak
Journal:  World J Psychiatry       Date:  2013-09-22

Review 2.  Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Authors:  Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams
Journal:  Neurosci Biobehav Rev       Date:  2016-09-14       Impact factor: 8.989

3.  Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students.

Authors:  M O Krebs; Y Morvan; T Jay; R Gaillard; O Kebir
Journal:  Mol Psychiatry       Date:  2014-01-21       Impact factor: 15.992

Review 4.  Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia.

Authors:  Melissa Fisher; Rachel Loewy; Kate Hardy; Danielle Schlosser; Sophia Vinogradov
Journal:  Annu Rev Clin Psychol       Date:  2013-01-07       Impact factor: 18.561

5.  Demographic and socioenvironmental predictors of premorbid marijuana use among patients with first-episode psychosis.

Authors:  Luca Pauselli; Michael L Birnbaum; Beatriz Paulina Vázquez Jaime; Enrico Paolini; Mary E Kelley; Beth Broussard; Michael T Compton
Journal:  Schizophr Res       Date:  2018-02-04       Impact factor: 4.939

6.  The role of cannabinoid 1 receptor expressing interneurons in behavior.

Authors:  Jacquelyn A Brown; Szatmár Horváth; Krassimira A Garbett; Martin J Schmidt; Monika Everheart; Levente Gellért; Philip Ebert; Károly Mirnics
Journal:  Neurobiol Dis       Date:  2013-11-13       Impact factor: 5.996

7.  Methamphetamine enhances the development of schizophrenia in first-degree relatives of patients with schizophrenia.

Authors:  Huabing Li; Qiong Lu; Enhua Xiao; Qiuyun Li; Zhong He; Xilong Mei
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

8.  Prevalence of lifetime nonmedical opioid use among U.S. Health Center Patients aged 45 years and older with psychiatric disorders.

Authors:  Jessica M Brooks; Emre Umucu; Karen L Fortuna; M Carrington Reid; Kathlene Tracy; Lusine Poghosyan
Journal:  Aging Ment Health       Date:  2020-12-09       Impact factor: 3.658

Review 9.  Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission.

Authors:  Sean C Godar; Marco Bortolato
Journal:  Front Behav Neurosci       Date:  2014-03-06       Impact factor: 3.558

Review 10.  Gone to Pot - A Review of the Association between Cannabis and Psychosis.

Authors:  Rajiv Radhakrishnan; Samuel T Wilkinson; Deepak Cyril D'Souza
Journal:  Front Psychiatry       Date:  2014-05-22       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.